<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increasing evidence indicates the important roles of M(3) muscarinic <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> receptors (M(3) mAChR) in the regulation and maintenance of cardiac function and <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, we investigated whether the M(3) mAChR mediates the cardioprotection against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and the mechanisms involved </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">Myocardial ischaemia</z:e> was established in Wistar rats by occlusion of the left anterior descending coronary artery </plain></SENT>
<SENT sid="3" pm="."><plain>Rats were treated with <z:chebi fb="0" ids="133341">choline chloride</z:chebi> (an M(3) mAChR <z:chebi fb="4" ids="48705">agonist</z:chebi>; 10 mg/kg, i.v.) 10 min before occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, 4-diphenylacetoxy-N-methylpiperidine-methiodide (4-<z:chebi fb="14" ids="17713">DAMP</z:chebi>; 0.12 μg/kg, i.v.) was administered 5 min before <z:chebi fb="3" ids="15354">choline</z:chebi> in the 4-<z:chebi fb="14" ids="17713">DAMP</z:chebi>-treated group </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischaemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> were evaluated in each group for a period of 1 h after occlusion </plain></SENT>
<SENT sid="6" pm="."><plain>After 24 h occlusion, protein and <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of L-type Ca(2+) channels and the <z:chebi fb="0" ids="29101">Na(+)</z:chebi> /Ca(2+) exchanger (NCX) were determined </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischaemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> following coronary <z:mp ids='MP_0006134'>artery occlusion</z:mp> were diminished by <z:chebi fb="3" ids="15354">choline</z:chebi> and this effect was reversed in the 4-<z:chebi fb="14" ids="17713">DAMP</z:chebi>-treated group </plain></SENT>
<SENT sid="8" pm="."><plain>In vitro, the effects of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> were simulated by incubating isolated ventricular cardiomyocytes with Tyrode's solution (pH 6.8) </plain></SENT>
<SENT sid="9" pm="."><plain>Intracellular Ca(2+) overload was confirmed and this was decreased by <z:chebi fb="3" ids="15354">choline</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, <z:chebi fb="3" ids="15354">choline</z:chebi> reduced the L-type Ca(2+) current (I(C) (a,) (L) ) compared with cardiomyocytes incubated in Tyrode's solution (pH 6.8) alone </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="3" ids="15354">Choline</z:chebi> reduced the '<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>'-induced upregulated expression of L-type Ca(2+) channels and NCX at both the protein and <z:chebi fb="2" ids="33699">mRNA</z:chebi> level </plain></SENT>
<SENT sid="12" pm="."><plain>Based on these results, <z:chebi fb="3" ids="15354">choline</z:chebi> has an obvious protective effect against <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> that is mediated via activation of cardiac M(3) mAChR, which reduces Ca(2+) overload mediated by L-type Ca(2+) channels and the NCX </plain></SENT>
</text></document>